Longwen Shang, Min Tsao, Zengliang Gao, Xuekui Zhang
{"title":"Estimating the joint distribution of two binary variables from marginal summaries in clinical trials.","authors":"Longwen Shang, Min Tsao, Zengliang Gao, Xuekui Zhang","doi":"10.1080/10543406.2026.2745677","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical trial simulation (CTS) is critical in new drug development, providing insight into safety and efficacy while guiding trial design before committing substantial investment. Achieving realistic outcomes in CTS requires an accurately estimated joint distribution of the underlying variables. However, privacy concerns and data availability issues often restrict researchers to marginal summary-level data of each variable obtained from publications, making it challenging to estimate the joint distribution due to the lack of access to individual-level data or relational summaries between variables. We propose a novel maximum likelihood approach to estimate the joint distribution of two binary variables using only marginal summary data from multiple published studies. By leveraging numerical optimization and accommodating varying sample sizes across studies, our method preserves privacy while bypassing the need for granular or relational data. Through an extensive simulation study covering a diverse range of scenarios and an application to a real-world dataset, we demonstrate the accuracy, robustness, and practicality of our method. This method enhances the simulation of realistic clinical trial data, thereby improving decision-making processes in drug development. To facilitate its implementation, we provide an open-source R package, ebdm, which is available on CRAN.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-16"},"PeriodicalIF":1.3000,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2026.2745677","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Clinical trial simulation (CTS) is critical in new drug development, providing insight into safety and efficacy while guiding trial design before committing substantial investment. Achieving realistic outcomes in CTS requires an accurately estimated joint distribution of the underlying variables. However, privacy concerns and data availability issues often restrict researchers to marginal summary-level data of each variable obtained from publications, making it challenging to estimate the joint distribution due to the lack of access to individual-level data or relational summaries between variables. We propose a novel maximum likelihood approach to estimate the joint distribution of two binary variables using only marginal summary data from multiple published studies. By leveraging numerical optimization and accommodating varying sample sizes across studies, our method preserves privacy while bypassing the need for granular or relational data. Through an extensive simulation study covering a diverse range of scenarios and an application to a real-world dataset, we demonstrate the accuracy, robustness, and practicality of our method. This method enhances the simulation of realistic clinical trial data, thereby improving decision-making processes in drug development. To facilitate its implementation, we provide an open-source R package, ebdm, which is available on CRAN.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.